Key Takeaways
- A pilot study found that balanced THC and CBD extracts significantly reduced pain and the need for painkillers in women with endometriosis.
- Patients reported pain intensity dropping from 6.81 to 4.59 out of 10 within three months, showing the potential of THC and CBD for endometriosis.
- The study revealed improvements in fatigue, anxiety, and overall quality of life, indicating a multifaceted benefit from cannabinoid treatment.
- The effective THC and CBD ratio matters, as THC targets pain receptors while CBD enhances overall well-being, both offering distinct benefits.
- Despite promising results, the study lacked a control group, highlighting the need for larger, well-designed trials to confirm findings on THC and CBD for endometriosis.
Endometriosis is one of those conditions where the gap between how much it hurts and how little medicine can do about it stays frustratingly wide. According to the World Health Organization, it affects roughly 190 million reproductive-age women globally, and diagnosis alone can take between four and 12 years. Once diagnosed, patients often rotate through NSAIDs, hormonal therapy, surgery, and eventually opioids, with no guarantee any of it sticks.
Against that backdrop, a new pilot study out of the Endometriosis Research Centre at Charité Berlin is drawing attention for a simple reason: patients on a balanced THC and CBD extract got measurably better, and stayed better, over a three-month stretch. Here’s what the researchers found, how it fits into the wider cannabinoid research picture, and why the formulation matters as much as the fact that cannabis was involved at all.
What Did the Charité Endometriosis Study Actually Test?
Researchers Kratz, Velho, Bock, Sehouli, and Mechsner ran a prospective, single-center cohort study at Charité’s Endometriosis Research Centre in Berlin. They enrolled 30 premenopausal women, aged 18 to 45, all with confirmed endometriosis and chronic pelvic pain that had resisted hormonal and analgesic treatment. Twenty-seven completed the full three months.
Every participant received an oral cannabinoid-based medicinal product, or CBMP, with a balanced THC:CBD ratio (12 mg THC and 14 mg CBD per ml), added on top of whatever treatment they were already using. Dosing started low and increased gradually over four weeks, landing at a target of roughly 10 mg THC and 12 mg CBD daily, split between a smaller morning dose and a larger evening one.
Outcomes were tracked using validated tools: a visual analog scale for pain, the Endometriosis Health Profile (EHP-30) for quality of life, plus scales for fatigue, anxiety, disability, and central sensitization. Nothing else about the participants’ care changed during the study, so any shifts in their scores were tracked against a stable baseline.
What Improved for Patients on Balanced THC and CBD?
The headline number: pain intensity dropped from a baseline of 6.81 out of 10 to 4.59 by month two, a statistically significant reduction that held through month three (p = 0.0004). Pain days fell too, from a median of 30 per month to 17 by the study’s end.
Just as notable, patients needed fewer painkillers to get there. Days requiring NSAIDs or opioids like tramadol and oxycodone dropped significantly (p = 0.0009), with seven participants who’d been actively using opioids at baseline cutting back over the course of treatment. For a condition where opioid dependence is a real and growing concern, that opioid-sparing effect is arguably as meaningful as the pain scores themselves.
Beyond pain, the study tracked improvements across:
- Fatigue (Chalder Fatigue Scale, p = 0.0013)
- Anxiety (GAD-7, p < 0.0001)
- Central sensitization, the nervous system’s tendency to amplify pain signals over time (CSI, p < 0.0001)
- Disability and daily functioning (Pain Disability Index, p < 0.0001)
- Overall quality of life across every domain of the EHP-30, including emotional well-being, self-image, and work impact
Side effects were mostly mild and clustered around the titration phase. Fatigue, concentration issues, and dry mouth were the most common complaints, and most symptoms eased as the weeks went on rather than getting worse.
Why Does the THC and CBD Ratio Matter So Much?
Here’s where the story gets more interesting than a simple “cannabis helps” headline. THC and CBD don’t work the same way in the body, and that detail is central to interpreting this research correctly.
THC binds to CB1 and CB2 cannabinoid receptors, which sit not just in the brain but in uterine tissue and endometriosis lesions themselves. That interaction dampens nociceptive signaling, the pain messages traveling through the nervous system.
CBD takes a different route, working through TRP channels and boosting the body’s natural endocannabinoid tone rather than directly targeting CB1 and CB2. Together, they hit pain, inflammation, mood, and sleep through overlapping but distinct mechanisms, something a single-target painkiller like ibuprofen simply can’t replicate.
That combination effect helps explain why the Charité formulation performed the way it did. It also explains why a separate 2026 trial called DREAMLAND, which tested a CBD-only oil rather than a balanced THC:CBD product, found no significant advantage over placebo for endometriosis-related pelvic pain. CBD alone and balanced THC:CBD extracts are not interchangeable, and conflating the two risks muddying what the evidence actually shows.
How Does This Study Fit Into the Larger Cannabis and Endometriosis Picture?
The Charité pilot doesn’t stand alone. It builds on a growing, if still uneven, body of research suggesting cannabinoids deserve serious attention in this space.
A 2024 survey led by some of the same Charité researchers polled 912 endometriosis patients across Germany, Austria, and Switzerland. Among the 345 who used cannabinoids for symptom management, cannabis was rated the most effective self-management strategy of any surveyed, with a mean score of 7.6 out of 10, and roughly 90% of users said it let them cut back on conventional pain medication.
Separately, an observational study using the UK Medical Cannabis Registry followed 101 women prescribed cannabis-based medicines for two full years. Improvements in pain, sleep, anxiety, and quality of life held steady across the entire period, and average opioid use fell from 19.9 mg of morphine equivalent daily to 14.8 mg.
None of these studies had a placebo arm, which is precisely why a properly randomized trial of balanced THC:CBD formulations, not just CBD alone, is the logical next step.
What Are the Limitations Worth Keeping in Mind?
The Charité researchers are upfront about their study’s limits. It was a small, single-center cohort with no control group, meaning it can’t rule out placebo response, regression to the mean, or the effect of patients simply expecting to feel better after trying something new. Everything was self-reported, and follow-up stopped at three months, so there’s no data yet on what happens after that window closes.
Endometriosis pain is also notoriously variable, and patients who seek out cannabinoid treatment after exhausting other options may carry higher expectations going in. That’s not a flaw unique to this study, it’s a challenge across most chronic pain research, but it’s worth naming.
None of this erases the findings. It just means the honest conclusion is “promising and worth a bigger trial,” not “problem solved.”
What Does This Mean for Endometriosis Patients Considering Cannabis?
Germany’s S2k clinical guideline already recognizes medical cannabis as a legitimate option for endometriosis patients aged 25 and older who haven’t found relief through conventional treatment, and prescriptions for balanced THC:CBD extracts are available through trained physicians there. That regulatory groundwork matters, because it means patients don’t have to wait for a large randomized trial to access a treatment their doctor believes is appropriate.
For patients elsewhere, the takeaway is more about the conversation than the prescription. The evidence doesn’t yet support declaring cannabis a proven endometriosis treatment, but it does support asking a doctor about balanced formulations specifically, rather than assuming any CBD product off a dispensary shelf will do the same job. Given how undertreated this condition remains, and how much patients already cycle through options with limited success, a treatment showing consistent signal across multiple independent studies deserves more than a passing mention.
The Case for a Bigger, Better-Designed Trial
The Charité pilot study won’t settle the debate over cannabis and endometriosis, and it was never designed to. What it does is add weight to a pattern showing up across multiple independent datasets: balanced THC:CBD formulations correlate with meaningful drops in pain, opioid use, and the broader symptom load that makes this disease so exhausting to live with.
The next move belongs to researchers, not marketers. A properly powered, placebo-controlled trial of standardized THC:CBD extracts, run over a longer timeline, would tell us whether these early numbers hold up. Until then, patients and clinicians have enough signal to take the conversation seriously, and enough uncertainty to keep expectations grounded.
Frequently Asked Questions
A small pilot study from Charité Berlin found that women who took a balanced THC:CBD oral extract for three months experienced less pain, fewer pain days, and reduced painkiller use. However, due to the study’s small size and lack of controls, the findings are preliminary and not yet conclusive.
CBD and THC work differently in the body, and are not interchangeable. Research shows that CBD-only oil is no more effective than a placebo, while a balanced THC:CBD extract has been found to produce significant improvements.
A Charité study found that participants experienced pain relief within the first month, which continued to improve over the next two months — all without needing to increase their dosage.
Two studies — one from Charité and one from the UK — found that cannabis-based medicines reduced the need for NSAIDs and opioids in patients with endometriosis. However, neither study included a placebo control group.
Yes. Germany’s S2k clinical guideline recognizes medical cannabis as a treatment option for chronic endometriosis pain in patients 25 and older who haven’t responded to conventional therapy. Specially trained physicians can prescribe THC:CBD extracts, which are often covered by health insurance.
